A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity, Safety, Tolerability, and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) (PYRUS)
Phase of Trial: Phase I
Latest Information Update: 24 Jun 2014
At a glance
- Drugs AZD 5363 (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms PYRUS
- Sponsors AstraZeneca
- 07 Jun 2017 Biomarkers information updated
- 18 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 07 May 2014 Planned End Date changed from 1 Feb 2015 to 1 Sep 2014 as reported by ClinicalTrials.gov record.